Li-Fraumeni syndrome (LFS) is a rare inherited condition that dramatically increases a person’s lifetime risk of developing cancer. Caused by a mutation in the TP53 gene, it pushes that risk to nearly 100% in women and about 75% in men by age 70. Half of all cancers in people with LFS appear before age 40, and many occur in childhood.
How TP53 Mutations Drive Cancer Risk
The TP53 gene produces a protein often called the “guardian of the genome.” Under normal circumstances, this protein stays at low levels in your cells. When something goes wrong, such as DNA damage, low oxygen, or a cell starting to grow abnormally, the protein activates and orchestrates a defense: it can pause the cell cycle to allow DNA repair, permanently retire a damaged cell, or trigger the cell to self-destruct entirely. It also maintains multiple DNA repair systems that fix errors before they become permanent.
In Li-Fraumeni syndrome, one copy of the TP53 gene carries a mutation from birth. This cripples the cell’s ability to catch and correct genetic damage. Over time, mutations accumulate unchecked, and cells that should have been stopped or destroyed instead keep dividing. Animal studies confirm this starkly: mice engineered to lack a functional version of this gene develop tumors with 100% incidence within months. Restoring the gene’s function, even in established tumors, can cause those tumors to shrink.
The Five Core Cancer Types
LFS is linked to an unusually broad range of cancers, but five types make up the majority:
- Soft-tissue sarcomas, cancers of muscle, fat, or connective tissue. Lifetime risk reaches about 22% in men and 15% in women.
- Osteosarcomas (bone cancer), with lifetime risk around 11% in men and 5% in women.
- Premenopausal breast cancer, the single largest risk for women with LFS, exceeding 60% lifetime risk.
- Brain tumors, affecting roughly 19% of men and 6% of women over a lifetime.
- Adrenocortical carcinomas, a rare cancer of the adrenal glands that is so uncommon in the general population that its presence, especially in a child, can be enough on its own to prompt genetic testing.
Beyond these five, people with LFS also face elevated risks for other cancers, including prostate cancer (25 to 50% lifetime risk in men), leukemia, lung cancer, and others. Many individuals develop more than one unrelated cancer over their lifetime, which is one of the syndrome’s hallmark features.
Cancer Risk in Children
One of the most striking aspects of LFS is how early cancer can appear. About 4% of babies with the mutation develop cancer in their first year of life. By age 5, that figure rises to 22%. By age 18, roughly 41% of children carrying the mutation will have been diagnosed with cancer. The childhood cancers most closely associated with LFS include adrenocortical carcinoma, a specific type of muscle cancer called rhabdomyosarcoma, and choroid plexus tumors (a rare brain cancer). Any of these in a young child, regardless of family history, is considered reason to test for a TP53 mutation.
How LFS Is Inherited
Li-Fraumeni syndrome follows an autosomal dominant inheritance pattern. That means only one mutated copy of the TP53 gene is enough to cause the condition. If one parent carries the mutation, each child has a 50% chance of inheriting it. Both sons and daughters can be affected, though women face higher overall cancer risk, largely because of the added burden of breast cancer.
Some cases arise without any family history at all. These “de novo” mutations occur spontaneously in the egg, sperm, or early embryo. A person with a new mutation can then pass it to their children in the standard 50/50 pattern.
How LFS Is Diagnosed
Diagnosis can be clinical (based on personal and family cancer history) or genetic (through TP53 testing). Clinicians use two main sets of criteria to decide who should be tested.
The classic criteria, established in 1969, require all three of the following: a sarcoma diagnosed before age 45, a first-degree relative (parent, sibling, or child) with any cancer before age 45, and another first- or second-degree relative with cancer before 45 or a sarcoma at any age.
The updated Chompret criteria cast a wider net. Testing is recommended if you developed one of the five core LFS cancers before age 46 and have a close relative with a core tumor before age 56. It also applies if you’ve had multiple primary cancers (two or more from the LFS spectrum, the first before age 46), if you developed breast cancer at age 31 or younger, or if you have one of three specific rare cancers: adrenocortical carcinoma, choroid plexus tumor, or a particular subtype of rhabdomyosarcoma. For these three rare cancers, no family history is needed to justify testing.
Genetic testing itself involves a blood sample analyzed for mutations in the TP53 gene. A confirmed pathogenic variant establishes the diagnosis even without a classic family history pattern.
Surveillance and Screening
Because no single organ system accounts for all the risk, surveillance for people with LFS is unusually comprehensive. Screening protocols typically include annual whole-body MRI to detect tumors early, along with brain MRI and additional targeted exams. Women generally begin breast screening with MRI in their 20s. Children undergo abdominal ultrasounds and other imaging at regular intervals to catch adrenocortical tumors and other childhood cancers as early as possible.
Early detection through these intensive protocols has been shown to improve outcomes. The goal is to catch cancers at a stage where they are smaller, more localized, and more treatable.
Treatment Considerations
Cancer treatment for someone with LFS follows many of the same principles as for anyone else, with one critical difference: radiation therapy poses a particular concern. Because the TP53 gene is central to repairing DNA damage, exposing cells to radiation in someone who already has impaired DNA repair can increase the risk of new, radiation-induced cancers in the treated area. When possible, treatment teams look for alternatives to radiation, or use it more sparingly and with careful planning.
Surgery remains a standard approach. For breast cancer, some women with LFS opt for preventive mastectomy given the very high lifetime risk. Treatment decisions are typically made in coordination with specialists who understand hereditary cancer syndromes, since the risk of developing additional primary cancers over a lifetime changes the calculus for how aggressively to screen and intervene at each step.
Genetic Testing for Family Members
Once a TP53 mutation is identified in one person, genetic testing becomes available for their relatives. Because the mutation carries a 50% chance of being passed to each child, testing allows family members to know their status and enter surveillance programs if needed. For those who test negative, the relief is significant: they carry no elevated risk and do not need the intensive screening schedule.
For families planning to have children, preimplantation genetic testing during IVF can identify embryos that do not carry the mutation. This option allows parents with LFS to have biological children without passing on the condition.